
Abbott Laboratories
CGM
Abbott Laboratories is the global leader in continuous glucose monitoring (CGM) technology through its revolutionary FreeStyle Libre system, headquartered in Abbott Park, Illinois, USA since 1888. With annual revenue of $44.328 billion in 2025, the company operates 100+ manufacturing and R&D facilities worldwide, employing 114,000+ people across 160+ countries. Abbott's Diabetes Care division alone generated $8.0 billion in 2025, driven by the FreeStyle Libre CGM franchise — the dominant platform in home-based glucose monitoring. The company's landmark $21 billion acquisition of Exact Sciences (roughly $23 billion enterprise value) announced in 2025 signals its strategic expansion into at-home cancer screening and precision oncology diagnostics.
Strengths: Unrivaled CGM technology with FreeStyle Libre achieving near-monopoly status in home diabetes monitoring; massive R&D investment exceeding $2.5 billion annually across diagnostics, medical devices, and nutrition; vertically integrated global manufacturing network spanning 100+ facilities worldwide; diversified revenue base reducing single-market dependency; and transformative $23 billion Exact Sciences acquisition positioning Abbott as the future leader in home-based cancer screening and diagnostics.
Weaknesses: Heavy dependence on the Diabetes Care segment for growth momentum; significant execution and integration risks associated with the $23 billion Exact Sciences acquisition; and intensifying competition from Dexcom's next-generation G7 CGM system in the rapidly expanding glucose monitoring market.Read MoreShow Less
Strengths: Unrivaled CGM technology with FreeStyle Libre achieving near-monopoly status in home diabetes monitoring; massive R&D investment exceeding $2.5 billion annually across diagnostics, medical devices, and nutrition; vertically integrated global manufacturing network spanning 100+ facilities worldwide; diversified revenue base reducing single-market dependency; and transformative $23 billion Exact Sciences acquisition positioning Abbott as the future leader in home-based cancer screening and diagnostics.
Weaknesses: Heavy dependence on the Diabetes Care segment for growth momentum; significant execution and integration risks associated with the $23 billion Exact Sciences acquisition; and intensifying competition from Dexcom's next-generation G7 CGM system in the rapidly expanding glucose monitoring market.
Listed market data
ABT · NYSE · weeklyHistory →- Market cap
- $185 B
- Share price
- USD 109.40
- 1Y change
- -14.8%
- Recent change
- -0.7%
- Since first close
- ×213
- Revenue (TTM)
- $45.1 B
11-02 → 11-03
from 1980-03
Financial history
Full market history- 2026-11USD 109.40$185 B+4.3%
- 2026-10USD 104.89$183 B+6.1%
- 2026-09USD 98.83$167 B-10.4%
- 2026-08USD 110.36$187 B+4.4%
- 2026-07USD 105.70$179 B+16.5%
- 2026-06USD 90.74$153 B+6.0%
- 2026-05USD 85.60$145 B-5.7%
- 2026-04USD 90.79$154 B-11.6%
- 2026-03USD 102.67$174 B-11.8%
- 2026-02USD 116.35$197 B+6.5%
- 2026-01USD 109.30$185 B-12.8%
- 2025-12USD 125.29$212 B—
Ownership & Control
Shareholding as of 2026-06-30- Controlling entity
- Publicly held — no controlling shareholder disclosed
- Company type
- Manufacturer
- Insiders
- 0.49%
- Institutions
- 81.90%(3,837 holders)
- Free float
- 82.31%
Percentages are of total shares outstanding, aggregated from 13F-style filings via Yahoo Finance. Institutional figures reflect US-filed positions and may undercount owners filing elsewhere. No figure is shown where none is disclosed.
In the press
All coverage →5 latest headlines- Abbott Laboratories Stock (ABT) Moved Up by 3.67% on Nov 2: A Full Analysis - TradingKeywww.tradingkey.com2026-11-02
- Abbott starts pivotal trial for mitral valve replacement device - MedTech Divewww.medtechdive.com2026-11-02
- Thomas H. Kean Jr reports Abbott Laboratories sale, ESAB purchase - Investing.comwww.investing.com2026-11-02
- Abbott's TECTONIC clinical trial demonstrates strong 30-day... - Quantisnowwww.quantisnow.com2026-11-01
- Can Abbott Laboratories (ABT) Stay Reasonable As Its Breakup Nears? - Yahoo Financefinance.yahoo.com2026-10-30
• ARCHITECT and Alinity immunoassay systems
• Clinical chemistry analyzers and integrated automation
• Hematology CELL-DYN, Alinity h-series
Rapid & Molecular Diagnostics – Core Business
• POC infectious disease testing BinaxNOW, ID NOW
• Molecular diagnostics platforms
Point-of-Care & Consumer Diagnostics – Core Business
• FreeStyle Libre continuous glucose monitoring
• i-STAT blood gas and critical care testing
Medical Devices & Monitoring – Core Business
• Structural heart, rhythm management, and neuromodulation devices
• Diabetes care systems beyond glucose monitoring
| Fiscal year | Revenue | Net income |
|---|---|---|
| 2025 | $44.3 B | $6.5 B |
| 2024 | $42 B | $13.4 B |
| 2023 | $40.1 B | $5.7 B |
| 2022 | $43.7 B | $6.9 B |
| 2021 | $43.1 B | $7 B |
Annual results from company filings (SEC XBRL), converted to US dollars.
Quick Facts
Headquarters
Abbott Park, Illinois, United States
Founded
1888
Employees
114,000
Revenue
USD$44.3 B (FY2025)
Market cap
$185 B
Factories
~100 manufacturing and R&D facilities globally
Presence
160+ Countries
Listing
NYSE: ABTCategories
24 categories · scroll for more
Related
Similar listed companies
- Eli Lilly and Company· $1.1 T
- Johnson & Johnson (J&J)· $658 B
- ASML Holding N.V.· $631 B
- Allergan Aesthetics· $521 B
- AbbVie Inc.· $521 B
- The Coca-Cola Company· $405 B
Data Sources & Methodology
This corporate profile is compiled from publicly available sources including company annual reports, SEC/regulatory filings, official press releases, and verified third-party industry databases. Financial figures reflect the most recent fiscal year disclosures and are cross-validated across multiple independent references.
VerityRank Score is calculated using a proprietary multi-dimensional model evaluating market presence, financial strength, operational scale, innovation capacity, and brand influence. Individual dimension scores are normalized against industry peers and updated quarterly.
Disclaimer: This profile is for informational purposes only. VerityRank makes no warranties regarding completeness or timeliness. This content does not constitute investment advice or endorsement.
Key references: Official Website NYSE: ABT , Data Sources & Methodology
Abbott Official Website
Abbott Laboratories - Wikipedia
Abbott 2025 Annual Report
Abbott Q1 2026 Earnings
